- Home
- TLRY vs XNCR Comparison
TLRY vs XNCR Comparison
Compare TLRY & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TLRY | XNCR |
|---|---|---|
| Founded | N/A | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 919.2M | 881.9M |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | TLRY | XNCR |
|---|---|---|
| Price | $6.76 | $12.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $72.33 | $22.33 |
| AVG Volume (30 Days) | ★ 5.9M | 690.7K |
| Earning Date | 04-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $8.79 | N/A |
| Revenue Next Year | $19.98 | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $0.36 | $6.92 |
| 52 Week High | $15.70 | $18.69 |
Technical Indicators
Market Signals| Indicator | TLRY | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.17 | 58.49 |
| Support Level | $6.13 | $12.19 |
| Resistance Level | $7.01 | $15.59 |
| Average True Range (ATR) | 0.54 | 0.68 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 13.26 | 84.51 |
Price Performance
Historical ComparisonAbout TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.